Denver Brown
Family · Branson, MONPI 1508235557
Payments from drug & device makers
Across 478 payments — averaging $15.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- AstraZeneca$1K
- Novo Nordisk$623
- Johnson & Johnson$542
- AbbVie$531
- Otsuka America Pharmaceutical, Inc.$401
- plus $2K from 30 others
What the payments were for
- Food & beverage$7,252100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 78 | $1,366 |
| AstraZeneca(2 entities) | 70 | $1,357 |
| Novo Nordisk | 100 | $623 |
| Johnson & Johnson | 36 | $542 |
| AbbVie | 26 | $531 |
| Otsuka America Pharmaceutical, Inc. | 23 | $401 |
| Amarin Pharma, Inc. | 15 | $208 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $205 |
| Abbott | 8 | $185 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $183 |
| Astellas Pharma US Inc | 9 | $175 |
| Boehringer Ingelheim | 9 | $139 |
| Lundbeck LLC | 7 | $120 |
| Sanofi-aventis U.S. LLC | 9 | $118 |
| GSK | 8 | $109 |
| Axsome Therapeutics, Inc. | 5 | $108 |
| Amgen | 5 | $107 |
| Pfizer | 6 | $99 |
| Merck | 6 | $95 |
| Biohaven Pharmaceuticals, Inc. | 5 | $76 |
| Vanda Pharmaceuticals Inc. | 2 | $60 |
| Novartis | 3 | $53 |
| Bayer | 3 | $50 |
| Sanofi | 2 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $49 |
| Jazz Pharmaceuticals Inc. | 3 | $46 |
| Kowa Pharmaceuticals America, Inc. | 3 | $42 |
| Genentech USA, Inc. | 3 | $42 |
| Boston Scientific | 1 | $28 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Dexcom, Inc. | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Mylan Specialty L.p. | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Exact Sciences | 1 | $13 |
| Organon | 1 | $9 |
How this compares
$7,264 in reported general payments places this provider in the 95th percentile of 3,812 family providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 87 | $98,132 |
| RexultiBrexpiprazole | 64 | $97,533 |
| TrulicityDulaglutide | 47 | $71,324 |
| FarxigaDapagliflozin Propanediol | 68 | $64,964 |
| VraylarCariprazine Hcl | 43 | $63,253 |
| MyrbetriqMirabegron | 67 | $47,274 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 27 | $40,179 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $32,719 |
| EliquisApixaban | 20 | $27,789 |
| JardianceEmpagliflozin | 12 | $16,958 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 19 | $16,945 |
| MounjaroTirzepatide | 14 | $14,825 |
| XareltoRivaroxaban | 17 | $14,002 |
| Varenicline Tartrate | 59 | $12,365 |
| LinzessLinaclotide | 17 | $9,180 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $1,357 | $105,14395 claims |
| Novo NordiskOzempic | $623 | $98,13287 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $401 | $97,53364 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,366 | $86,14961 claims |
| AbbVieVraylar, Linzess | $531 | $72,43360 claims |
| Astellas Pharma US IncMyrbetriq | $175 | $47,27467 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $139 | $33,90331 claims |
| GSKTrelegy Ellipta | $109 | $32,71936 claims |
| PfizerEliquis | $99 | $27,78920 claims |
| Johnson & JohnsonXarelto | $542 | $14,00217 claims |
| MerckBelsomra | $95 | $7,05016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,812 family providers in Missouri.
Other family in Branson
- Hollie HolderfieldBranson$13K
- Connie SpencerSaint Joseph$320K
- Shayla SandersKansas City$306K
- Tamera WolfLees Summit$215K
- Tiffany ArnoldFestus$177K
- Tiffany NelsonSedalia$164K
- Chelsey BeckerSaint Peters$104K
- Carey PattonDes Peres$94K
- Marcy MarkesColumbia$92K
- Laura HedigerSpringfield$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.